Differentiated Thyroid Cancer Clinical Trials

69 clinical trials for Differentiated Thyroid Cancer across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors — RECRUITING · PHASE1
• Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) — RECRUITING · PHASE2
• Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy — RECRUITING
• Pembrolizumab in High-risk Thyroid Cancer — RECRUITING · PHASE2
• Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers — RECRUITING · NA
• F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer — RECRUITING · NA
• Iodine Uptake After a Low Iodine Diet — RECRUITING · NA
• Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer — RECRUITING · PHASE2
• Targeted Therapy to Increase RAI Uptake in Metastatic DTC — RECRUITING
• The EMIRATES Study — RECRUITING
• Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer — RECRUITING
• Sacituzumab govitEcan in THYroid Cancers — RECRUITING · PHASE2
• HiLo: Multicentre randomised phase III clinical trial of high versus low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation following surgery for differentiated thyroid cancer — OTHER · PHASE3
• A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection. — COMPLETED
• Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Lenvatinib in Locally Advanced Invasive Thyroid Cancer — COMPLETED · PHASE2
• Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial — NOT_YET_RECRUITING · PHASE1
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study — NOT_YET_RECRUITING · PHASE3
• Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. — COMPLETED · PHASE2
• Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma — COMPLETED
• Decision Aid Efficacy in Low Risk Thyroid Cancer — NOT_YET_RECRUITING · NA
• Empirical Radioactive Iodine Therapy in DTC — NOT_YET_RECRUITING · PHASE1
• Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy — ACTIVE_NOT_RECRUITING · NA
• Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy — NOT_YET_RECRUITING
• IDEntification of New Predisposition Genes in Differentiated THYroid Cancer — TERMINATED · NA
• Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer — COMPLETED · PHASE1
• Robotic Surgery Via Bilateral Axillo-breast Approach for Relatively Low-risk Papillary Thyroid Carcinoma With Lateral Cervical Lymph Node Metastasis: a Safe and Effective Cosmetic Procedure in the Context of Prevalent Thyroid Ultrasound Screening — COMPLETED
• A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy — ACTIVE_NOT_RECRUITING · PHASE3
• Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid Cancer: Insight From Middle Eastern Cohort — COMPLETED
• [18F]Tetrafluoroborate PET/CT for the Detection of Differentiated Thyroid Cancer: A Phase II Imaging Study — TERMINATED · PHASE2
• Primary Care Transfer for Thyroid Cancer Patients — ACTIVE_NOT_RECRUITING · NA
• Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer — COMPLETED · PHASE3
• Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients — OTHER · NA
• Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal — COMPLETED · PHASE3
• Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients — COMPLETED · PHASE1
• Recurrence in Patients With Differentiated Thyroid Cancer — OTHER
• A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer — COMPLETED · PHASE1
• The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. — OTHER · PHASE2
• Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer — OTHER · PHASE3
• Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET) — OTHER · NA
• Investigating National Solutions for Personalised Iodine-131 Radiation Exposure — OTHER
• Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer — OTHER · PHASE2
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma — COMPLETED · PHASE1
• Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer — OTHER · PHASE3
• A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China — COMPLETED · PHASE3
• A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer — TERMINATED · PHASE3
• 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis — COMPLETED · NA
• Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone — OTHER · PHASE2
• A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting — OTHER · PHASE2

Refine this search